Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

were
  • North America: 82.5% (85/103) for 900-mcg albinterferon alfa-2b, vs. 81.5% (88/108) for peginterferon alfa-2a;
  • Asia: 79.8% (75/94) for 900-mcg albinterferon alfa-2b, vs. 95.5% (85/89) for peginterferon alfa-2a;
  • Europe: 78.1% (64/82) for 900-mcg albinterferon alfa-2b, vs. 81.7% (67/82) for peginterferon alfa-2a;
  • Other regions: 75.8% (25/33) for 900-mcg albinterferon alfa-2b, vs. 74.2% (23/31) for peginterferon alfa-2a.
  • Patients receiving 900-mcg albinterferon alfa-2b had comparable rates of serious adverse events, severe adverse events, and discontinuations due to adverse events, vs. peginterferon alfa-2a.
  • The incidence of severe and/or serious adverse events was comparable between the two groups, with 17.3% (54/313) in the albinterferon alfa-2b 900-mcg treatment group, vs. 17.5% (54/309) in the peginterferon alfa-2a treatment group.
  • The incidence of severe and/or serious pulmonary adverse events was also comparable between these groups: severe and/or serious pulmonary infections were 0.6% (2/313) for 900-mcg albinterferon alfa-2b, vs. 0.6% (2/309) for peginterferon alfa-2a; and severe and/or serious respiratory, thoracic or mediastinal disorders were 1.0% (3/313) for 900-mcg albinterferon alfa-2b, vs. 1.3% (4/309) for peginterferon alfa-2a.
  • Overall, adverse events observed were those typically associated with interferon therapy, and the rate of discontinuations due to adverse events was comparable: 4.8% (15/313) for 900-mcg albinterferon alfa-2b, vs. 3.6% (11/309) for peginterferon alfa-2a.
  • Treatment Group Originally Randomized to Receive Albinterferon Alfa-2b 1200-mcg Every Two Weeks and Reduced to 900-mcg Following January 2008 Dose Modification, vs. Treatment Group Receiving Peginterferon Alfa-2a 180-mcg Every Week

    Due to the dose modification announced in J
    '/>"/>

    SOURCE Human Genome Sciences, Inc.
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
    2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
    3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
    4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
    5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
    6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
    7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
    8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
    9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
    10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
    11. Premier Research Appoints Global Head of Human Resources
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
    (Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
    (Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
    (Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
    Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
    ... ROCKVILLE, Md., March 9, 2012 EntreMed, Inc. (Nasdaq: ... therapeutics for the treatment of cancer, today reported results ... 31, 2011.   (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) ... $1.9 million compared to $3.7 million for fiscal 2010. ...
    ... SQUARE, Pa., March 8, 2012  On the occasion of ... announce that interim data from an expanded clinical trial ... for safety and improved quality of life (QOL) previously ... The probiotic microbial strains in the product formulation are ...
    ... from North Carolina State University have developed the first ... in electronics, opening the door to an array of ... first time that researchers have been able to produce ... in a single oxide material, launching a new era ...
    Cached Biology Technology:EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results 4EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results 5Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function 2Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function 3Functional oxide thin films create new field of oxide electronics 2
    (Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
    (Date:7/11/2014)... the normal circumstances, astrocytes participate in normal ... and exhibit therapeutic and repairing effects on ... have found that nerve cells differentiated from ... reduced viability, which produces influences on subsequent ... General Hospital, Hebei United University, China demonstrated ...
    (Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
    Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Blame it on the astrocytes 2
    ... Dr. Eeva Karjalainen, of the Finnish Forest Research Institute, Metla, ... But not many of us know that there is also ... Forests and other natural, green settings can reduce ... happiness. Forest visits may also strengthen our immune system by ...
    ... This release is also available in ... also known as angiogenesis, is crucial for sustained tumor ... suppress the growth of these vessels have been available ... detection and quantification of blood vessel growth using nonsurgical ...
    ... distinguished government scientist Professor Robert (Bob) Watson who becomes ... Chief Scientific Advisor to the Department of Environment, Food ... Professor Watson is recognised for his contributions to scientific ... global warming. Professor Peter Heathcote, Head of the ...
    Cached Biology News:Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 3Honorary Fellowship awarded to government Chief Scientific Advisor 2
    Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
    ...
    ... genetically encoded fluorescent sensor capable for high ... one of the main ROS generated by ... fluorescent protein inserted into the regulatory domain ... demonstrates submicromolar affinity to H2O2 and at ...
    Alexa Fluor 647 anti-mouse Qa-2...
    Biology Products: